bioAffinity Technologies (BIAFW) EBITDA (2021 - 2026)

bioAffinity Technologies has disclosed EBITDA across 6 years of filings, most recently posting -$3.6 million for Q1 2026.

• In Q1 2026, EBITDA fell 39.06% year-over-year to -$3.6 million; the TTM figure through Mar 2026 stood at -$11.4 million (down 20.52% YoY), while the FY2025 annual figure was -$10.4 million, down 18.33% from the prior year.
• EBITDA fell to -$3.6 million in Q1 2026, from -$3.1 million in the prior quarter.
• Over the last five years, EBITDA for BIAFW reached as high as -$684119.0 in Q2 2022 and fell as low as -$3.6 million in Q1 2026.
• The 5-year median for EBITDA is -$2.0 million (2024), against an average of -$2.0 million.
• Annual changes were most pronounced in 2023 — EBITDA tumbled 156.88% — and 2024, when it increased 14.05%.
• A 5-year view of EBITDA shows it stood at -$1.6 million in 2022, then plunged by 34.62% to -$2.2 million in 2023, then slumped by 33.44% to -$2.9 million in 2024, then slipped by 6.74% to -$3.1 million in 2025, then slipped by 15.91% to -$3.6 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$3.6 million, -$3.1 million, and -$2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.